Gastrointestinal cancers metastasize to regional lymph nodes by direct extension, via the portal circulation and, ultimately, anywhere in the body. A search for metastatic disease is important at the time of original presentation of these cancers since the presence of metastases often changes the treatment plans. After initial treatment, follow-up strategies are often used to detect subsequent metastases, even though (with the notable exception of colorectal metastases in the liver) the discovery of metachronous metastases has prolonged the lives of only a small number of patients.
Pancreatic Cancer
Imaging techniques are most useful for determining resectability of primary pancreatic cancers. Accuracy of predicting lymph node metastases is similar to that described above.
Magnetic Resonance Imaging
MRI is a commonly used modality for the detection of metastases from gastrointestinal malignancies. MRI cholangiopancreatography and MRI with gadolinium are especially useful for the detection of hepatic metastases and the differentiation of metastatic disease from benign liver lesions. Hepatic metastases usually have low signal intensity on T1-weighted images. A central high-intensity area may represent hemorrhage or necrosis. 16 Heavily weighted T2 images with dynamic gadolinium enhancement help to differentiate malignant lesions in the liver from cysts and hemangiomas. Focal nodular hyperplasia and fatty infiltration of the liver, sometimes difficult to distinguish from metastatic lesions on CT, are usually correctly diagnosed using MRI techniques.
Tumor Markers
A wide variety of tumor-associated molecules have been described in gastrointestinal malignancies. The use of serum measurements of these molecules has been used to assess patients prior to initial surgery and to follow patients under surveillance for recurrence. In the early 1950s, Owen Wangensteen, recognizing that as many as 50% of patients with colorectal cancer operated on for cure died of recurrent disease, proposed the idea of a "second-look" operation to assess and resect residual or recurrent disease. Reoperation typically took place six months after definitive surgery. He found that 50% of eligible patients were operated on without finding cancer and that most who had cancer were not resectable. 17, 18 Only 6.2% of patients with cancer survived for five years, and the concept was largely abandoned. By the 1980s, however, CT scanning and carcinoembryonic antigen (CEA) assay had become available, and the idea of a "second-look" operation was given a second look.
A large trial was reported in 1985 on data collected from 31 institutions. 19, 20 Of the 400 patients who were followed after curative surgery with serial serum CEA determinations, 130 (32.5%) had recurrences detected by symptoms or rising CEA. Seventy-five underwent second-look operation, and 39 had a curative procedure. Half of the operations and resections were done for symptoms and half for rising CEA. No tumors were found on five patients operated on for rising CEA, although two patients subsequently proved to have recurrences. Only 15 patients were disease free at the time of publication. In sum, only 4% of the original 400 patients had long -term benefit from the second-look procedure, and only 2% were affected by CEA result. The authors concluded that (1) patients with Dukes' A colon cancer need not be followed with CEA because none of these patients in the study had a recurrence, (2) one quarter of patients with Dukes' B1, B2, or C1 cancers had a recurrence and one half of Dukes' C2 lesions recurred, implying these patients should be followed with CEA determinations, (3) one-to two-month intervals were most effective in detecting recurrent disease, and (4) reoperation should take place before CEA values exceed 11 ng/mL since the highest resectability and survival rates were noted in this group. Schneebaum et al 21 studied the ability of CEA level to predict resectability of recurrence and concluded that although patients with higher CEA levels were less likely to be resected for cure, the large standard deviation in the values did not justify exclusion of patients from consideration of resection based on CEA levels alone.
Moertel et al 22 studied 1,017 patients evaluated for resection based on symptoms or rising CEA levels and found that 2.9% benefitted from resection of tumor identified by rising CEA titer. In both studies of resection of colorectal cancer recurrence, the majority of the resected tumors were found in the liver or "wound seeds."
Radioimmunoguided Surgery
Noting that 50% of patients with colorectal cancer develop recurrence, that the resectability of recurrences ranges from 12% to 60%, and that only 20% to 40% of patients reresected for cure are disease free five years later, the Ohio State group employed a novel strategy to identify recurrent or persistent residual disease. 23 This approach uses antitumor-associated glycoprotein murine monoclonal antibody tagged with I-125 that is injected into patients prior to exploration. At the time of operation, a hand-held gamma detection probe is used to locate the radioisotope. Two antibodies (B72.3 and CC49) were used in 131 patients, and 81 (63%) of them were found to be unresectable either by traditional surgical criteria or by radioimmunoguided surgery (RIGS). In 49 patients who were resected by a combination of traditional surgical assessment and RIGS criteria, 27 (55%) were alive at the time of publication, some two to eight years after exploration. Neither site of tumor resection nor Kaplan-Meier survival statistics were reported.
Cancer Cells in the Circulation and Bone Marrow

Bone Marrow and Peripheral Blood
Immunohistochemistry, flow cytometry, and polymerase chain reaction (PCR) techniques have been used to identify the presence of cancer cells in the peripheral blood and bone marrow of patients with gastrointestinal malignancies.
Using flow cytometry, O'Sullivan et al 24 . In a group of 20 colorectal cancer patients evaluated one to nine years after resection, 18 were free of disease and had negative bone marrows. Two had micrometastases, and one of these was found to have recurrence.
Using reverse transcription PCR, Soeth et al 25 evaluated both bone marrow and venous blood isolates from patients with gastrointestinal malignancies for evidence of micrometastases. They found 31% positive bone marrow and 17% venous isolates in patients with colorectal cancer. The presence of micrometastases correlated with stage of tumor. In gastric cancer and pancreatic cancer patients, a higher detection rate was found in the bone marrow when compared to peripheral blood. Survival in patients with PCR evidence of micrometastases was significantly shorter than in patients who tested negative.
To determine if micrometastases found in the bone marrow at the time of initial resection are evidence of shed cancer cells or a marker for metastatic potential, O'Sullivan et al 26 examined the bone marrows of carefully staged patients with gastrointestinal malignancies before and after they underwent "curative" surgery. Micrometastases were detected in 16 (22%) of 72 patients. In the 16 patients, subsequent bone marrow assessments were negative in 11 patients but persisted in five patients. This group represents a subset of patients with true residual disease. Detection of micrometastases postoperatively was associated with the discovery of overt metastasis during short follow-up (nine of 19 patients within 18 months), a highly significant finding when compared with patients who tested negative for micrometastases.
PCR techniques have been used to examine lymph nodes from the resected specimens of patients with gastrointestinal cancers. The expression of CEA mRNA in lymph nodes was assessed using a CEA-specific nested reverse transcriptase-PCR assay. 26 In 117 lymph nodes from a variety of cancer patients, 30 were histologically positive for metastases and all were positive for CEA mRNA. Of 87 histologically negative nodes, 47 were positive for CEA mRNA.
